Arch Venture Partners
8755 West Higgins RoadChicago, IL 60631-2176
Firm Size
- Assets Under Management (AUM):$10.6 Billion
- Number of Funds:13
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Description
ARCH Venture Partners is a venture capital firm based in Chicago, Illinois. Founded in 1986, it primarily focuses on investing in early-stage technology companies in the fields of life sciences, physical sciences, and information technology. ARCH Venture Partners has a strong track record of successful investments and has partnered with numerous industry-leading companies and entrepreneurs. The firm has a team of experienced professionals with deep industry knowledge, and it provides its portfolio companies with capital, strategic guidance, and access to a network of resources to accelerate their growth and success. ARCH Venture Partners is a respected player in the venture capital industry, known for its expertise in identifying promising startups and helping them achieve their full potential.Latest News
Powered by
Feb 27, 2024: Matter Neuroscience Secures $26M in Funding to Cure Unhappiness
Matter Neuroscience, the company working to unlock a deeper understanding of happiness and well-being by providing people with personalized insights into their brain chemistry emerges from stealth mode today. Matter announced it has received $26 million in funding, initial funding seeded by Polaris Partners and a more recent round co-led by ARCH Venture Partners, Polaris Partners, and Exor Ventures, and joined by Collaborative Fund and others. With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.
Jan 04, 2024: HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases
Human Immunology Biosciences (HI-Bio ™ ), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.
Jan 03, 2024: Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease
Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company) along with new investors WTT Investment, Willett Advisors, and others. The funds will support clinical development of the company's lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.
Nov 01, 2023: Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics
Gate Bioscience, a biotechnology company creating a new class of medicines called Molecular Gates, today unveiled the company and its scientific platform. Founded in 2021, Gate is emerging from stealth with a novel scientific platform; a world-class management and advisory team with a significant track record of success; and $60M in Series A funding led by Versant Ventures and a16z Bio + Health, with participation from ARCH Venture Partners and GV.
Sep 19, 2023: Magnet Biomedicine Emerges from Stealth with $50 Million to Advance Rational Approach to Molecular Glues with TrueGlue™ Discovery Platform
Magnet Biomedicine, a biotechnology company advancing molecular glue discovery with rational selection and design, today announced a $50 million Series A financing co-led by founding and initial investor, Newpath Partners, and ARCH Venture Partners. Magnet is reimagining what is achievable with molecular glues by looking beyond known protein–protein interactions and analyzing the broad protein landscape to pair target proteins with rationally selected presenter proteins to drive therapeutic effects.
Aug 17, 2023: TFC Therapeutics Launches to Advance Novel Platform and Technologies in Cancer Biology
TFC Therapeutics (TFC), a biotechnology company focused on developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis, today announced a financing led by ARCH Venture Partners with participation from Breakout Ventures, Alexandria Real Estate Equities, and Alumni Ventures. In connection with the financing, Steven Gillis , Ph.D., Managing Director at ARCH, has been appointed as Chairman of the TFC Board of Directors.
Jul 14, 2023: ARCH Venture Partners Announces Appointment of Kent Rogers as Venture Partner
ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Kent Rogers as Venture Partner.
May 25, 2023: ARCH Venture Partners Announces Appointment of Kevin Hrusovsky as Venture Partner
ARCH Venture Partners today announced the appointment of life sciences industry veteran Kevin Hrusovsky as Venture Partner.
May 23, 2023: ARCH Venture Partners Announces Appointment of Jami Rubin as Venture Partner
ARCH Venture Partners today announced the appointment of life sciences industry veteran Jami Rubin as Venture Partner.
May 18, 2023: OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The Company concurrently raised $14 million in new funding from existing investors, led by RiverVest Venture Partners and including ARCH Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, InterVest and others.
May 18, 2023: Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline
Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures. All existing investors, including Newpath Partners, 8VC and Alexandria Venture Investments, also participated.
Apr 06, 2023: ARCH Venture Partners Announces Appointment of Brian Cuneo as Senior Partner
ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Brian Cuneo as Senior Partner.